Neuroblastoma is the second most common solid childhood tumor and the outlook for patients with limited disease (25% of the cases) is good. However, with more advanced or metastatic disease, complex and demanding combinations of surgery, chemotherapy, and radiotherapy are required. Even with these treatment modalities the goal of cure remains frustratingly elusive in many patients.
KeywordsTotal Body Irradiation Autologous Bone Marrow Transplantation Proc ASCO Dose Melphalan Bone Marrow Rescue
Unable to display preview. Download preview PDF.
- 4.Carli M, Green AA, Hayes FA, Rivera G, Pratt CB (1982) Therapeutic efficacy of single drugs for childhood neuroblastoma: a review. In: Raybaud C (ed) Proceedings of the XIIIth SIOP Meeting, Marseille. Excerpta Medica, Amsterdam, pp 141–150Google Scholar
- 8.Pritchard J, Germond S, Jones D, De Kraker J, Love S (1986) Is high dose melphalan of value in treatment of advanced neuroblastoma? Preliminary results of a randomized trial by the European neuroblastoma study group. Proc ASCO 5: 205Google Scholar
- 9.Voute PA, Hoefnagel CA, De Kraker J, Marcuse HR (1986) 131I-meta-iodobenzylguanidine (131I-MIBG) as targeted radio-isotope in treatment of children with neuroblastoma. Proc ASCO 5: 213Google Scholar
- 10.Kemshead JT, Goldman A, Jones D, Pritchard J, Malpas JS, Gordon I, Malone JF, Hurley GD, Breatnach F (1985) Therapeutic application of radiolabelled monoclonal antibody UJ13A in children with disseminated neuroblastoma. A phase 1 study. Adv Neuroblastoma Res 4: 533–544Google Scholar